Phase 4 Type 2 Diabetes Trial, Recruiting NCT06410352 Sponsor: University Medical Center, Kazakhstan Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 4 Type 2 Diabetes Trial, Recruiting

NCT06410352
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give written consent to participate
  • People who have had type 2 diabetes for at least 3 years and are currently using glucose-lowering treatment that includes insulin
  • People who are between 35 and 55 years old
  • People of Asian ethnicity with a body mass index (BMI) of 27 or higher
  • People who are currently taking medication to treat high blood pressure
  • People who have lost between 15% and 20% of their body weight at the start of the study, with follow-up monitoring for up to 24 weeks

Who may not be able to join:

  • People who have type 1 diabetes
  • People who are younger than 35 or older than 55 years of age
  • People with serious or unstable heart conditions, such as severe heart failure, hard-to-treat chest pain, uncontrolled irregular heartbeat, serious heart valve problems, or severely uncontrolled high blood pressure
  • People whose kidneys are not functioning well (low filtration rate below 30 mL/min) or who have had dialysis within 14 days before the screening visit
  • People who have had a cancer diagnosis within the past 5 years
  • People who are pregnant or breastfeeding
  • People with an inherited (hereditary) medical condition
  • People who are known to be allergic to any of the substances being tested in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Kuat Oshakbayev, professor, University Medical Center, Kazakhstan

Phone: +77013999394

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
University Medical Center, Kazakhstan
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
30 September 2025

Where this trial is recruiting

🇰🇿 Kazakhstan

Primary endpoints

Weight; Body mass index; Fat mass; Fat free mass; blood insulin level; systolic/diastolic Blood presure; Fasting blood glucose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov